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Abstract
 
Immunoprecipitating IgG autoantibodies to glutamic acid
decarboxylase, GAD
 
65
 
, and/or a tyrosine phosphatase, IA2,
are present in the majority of individuals experiencing pan-
creatic 
 
b
 
 cell destruction and development of type 1 diabe-
tes. Here we identify a third islet cell autoantigen, a novel
38-kD protein, which is specifically immunoprecipitated
with sera from a subset of prediabetic individuals and newly
diagnosed type 1 diabetic patients. The 38-kD autoantigen,
named glima 38, is an amphiphilic membrane glycoprotein,
specifically expressed in islet and neuronal cell lines, and
thus shares the neuroendocrine expression patterns of
GAD
 
65
 
 and IA2. Removal of N-linked carbohydrates results
in a protein of 22,000 
 
M
 
r
 
. Glima 38 autoantibodies were de-
tected in 16/86 (19%) of newly diagnosed patients, including
three very young children, who had a rapid onset of disease,
and in 6/44 (14%) of prediabetic individuals up to several
years before clinical onset. The cumulative incidence of
GAD
 
65 
 
and glima 38 antibodies in these two groups was 83
and 80%, respectively, and the cumulative incidence of
GAD
 
65
 
, glima 38, and IA2 antibodies in the same groups
was 91 and 84%, respectively. GAD
 
65
 
, IA2, and glima 38
represent three distinct targets of immunoprecipitating IgG
autoantibodies associated with 
 
b
 
 cell destruction and type 1
diabetes. (
 
J. Clin. Invest. 
 
1996. 97:2772–2783.) Key words:
insulin-dependent diabetes mellitus 
 
•
 
 islet 
 
•
 
 autoantibodies 
 
•
 
autoantigen 
 
•
 
 membrane glycoprotein
 
Introduction
 
Pancreatic 
 
b
 
 cells in islets of Langerhans can be destroyed by
autoimmune processes resulting in insulin-dependent or type 1
diabetes (1). The destruction often proceeds over a long pe-
riod of time before the clinical symptoms develop (2, 3). The
gradual loss of 
 
b
 
 cells is accompanied by circulating islet cell
antibodies demonstrated by indirect immunofluorescence
staining of frozen sections of human pancreas (ICA)
 
1
 
 (2, 3).
Although 
 
b
 
 cell destruction is believed to be mediated by T
cells (4), islet cell antibodies detected in the early phases of 
 
b
 
cell destruction are likely to be directed to the same antigen(s)
as pathogenic T cells. Furthermore, antigen-specific B lympho-
cytes may play an important role in presentation of rare 
 
b
 
 cell
autoantigens to maintain a chronic autoimmune response that
gradually depletes the 
 
b
 
 cell pool. ICA epitopes are usually
only detected on frozen but not on fixed pancreatic tissue, con-
sistent with their conformational nature. Immunoprecipitation
of islet cell lysates in the presence of nonionic detergents,
which preserve the conformation of proteins, has identified the
smaller form of the neuroendocrine enzyme glutamic acid de-
carboxylase (GAD
 
65
 
) (5, 6) and a 40-kD tryptic fragment of
the tyrosine phosphatase (IA2) (7–9) as targets of islet cell an-
tibodies associated with early as well as late stages of 
 
b
 
 cell de-
struction in 70–80% and 50–80% of patients, respectively (5–8,
and references therein). Sequence analyses of the immunoglo-
bulin genes encoding GAD
 
65
 
 autoantibodies have provided
convincing evidence that the development of these antibodies
is antigen driven and can involve many rounds of antigen se-
lection (10). Reactivity with denatured carboxypeptidase H
(11), a 52-kD protein (12), and a 69-kD protein with homology
to BSA (13) on Western blots has also been reported in some
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diabetic sera. However, the proteins identified by immuno-
blotting are unlikely to be targets of ICA in the majority of
sera which only react on frozen (nondenaturing conditions) but
not fixed (denaturing conditions) sections of human pancreas.
GAD
 
65
 
 is the synthesizing enzyme for the major inhibitory
neurotransmitter 
 
g
 
-amino butyric acid (GABA) and is ex-
pressed in significant amounts in 
 
b
 
 cells and in GABA-ergic
neurons (14). GABA may function as a paracrine signaling
molecule in pancreatic islets (14). The diabetes-associated
epitopes in GAD
 
65
 
 are predominantly conformational and
only include a linear epitope in very rare cases (5, 15, 16). IA2
belongs to a family of membrane-spanning tyrosine phos-
phatases, but its membrane compartment in 
 
b
 
 cells has not yet
been identified (8, 9). Autoantibodies in insulin-dependent di-
abetes mellitus are directed to conformational epitopes in the
COOH-terminal half of the protein, which is likely to be cyto-
solic (8, 9). This region of the protein encompasses the 40-kD
tryptic fragment, which was originally identified in trypsinated
immunoprecipitates of rat islet cell proteins using type 1 dia-
betic sera (7). A 37-kD tryptic fragment detected in concert
with the 40-kD fragment is derived from a cross-reactive ty-
rosine phosphatase (9) but does not seem to constitute an in-
dependent autoantigen. The amino acid sequence of IA2 pre-
dicts a molecular mass of 105 kD, but the precursor of the
40-kD tryptic fragment in islets seems to migrate as a diffuse
band, at a much lower relative molecular mass of 
 
z
 
 64,000
D(8). The reason for this difference in the predicted and ap-
parent size of the islet protein on SDS gels is not clear and ac-
curate identification of the IA2 antigen in SDS-PAGE analysis
of immunoprecipitates of islet cell lysates with diabetic sera re-
quires trypsinization. A partial cDNA clone of IA2 (52 kD)
was independently identified by antibody screening of an islet
cell cDNA library using a serum from a diabetic patient (17).
The COOH-terminal region of IA2 also contains the single
tentative catalytic tyrosine phosphatase domain. This domain
has nonconserved amino acid substitutions in residues critical
for enzyme activity, and tyrosine phosphatase activity of IA2
remains to be demonstrated (9). IA2 is expressed in pancreatic
islets and in brain (9). Thus both GAD
 
65
 
 and IA2 are neuroen-
docrine enzymes.
We have sporadically detected an antigen with a molecular
mass of 38 kD in immunoprecipitates of nontrypsinated rat is-
let cell proteins using human type 1 diabetic sera and native
conditions (our unpublished results). Antibodies to a protein
of a similar relative molecular mass have been reported in the
BB rat, an animal model of type 1 diabetes (18). T cell reactiv-
ities to a 38-kD rat insulinoma protein, imogen 38 (19), and to
the 38-kD nuclear transcription factor jun-B (20) have also
been detected in newly diagnosed diabetic patients. We now
report that a vigorous extraction of islet cell proteins in deter-
gent results in a consistent detection of a 38-kD 
 
b
 
 cell antigen
in immunoprecipitates with a subgroup of type 1 diabetic sera.
The difficulty in extracting the 38-kD protein indicates that it
is relatively insoluble and thus has escaped detection in many
previous immunoprecipitation analyses with type 1 diabetic
sera. Using an improved extraction method for solubilizing is-
let cell proteins, we have analyzed the incidence of 38-kD au-
toantibodies in newly diagnosed and prediabetic individuals
and determined different characteristics of the 38-kD antigen.
The results demonstrate that the 38-kD protein is a novel tar-
get of autoantibodies in a subset of prediabetic and diabetic
patients and is distinct from both imogen 38 and jun B.
 
Methods
 
Preparation of islet cell extracts and immunoprecipitation analysis of
GAD
 
65
 
 and 38-kD antibodies.
 
Neonatal rat islets were isolated and
labeled with [
 
35
 
S]methionine as described (21). Islets were swollen on
ice for 10 min in HEMAP buffer (10 mM Hepes, pH 7.4, 1 mM
MgCl
 
2
 
, 1 mM EGTA, 1 mM aminoethyl-isothiouronium bromide hy-
drobromide, and 0.2 mM pyridoxal phosphate), followed by homoge-
nization by 20 strokes in a glass homogenizer. The homogenate was
centrifuged at 100,000 
 
g 
 
for 1 h to obtain a cytosol and a particulate
membrane fraction. The particulate membrane fraction was extracted
in HEMAP buffer with 2% Triton X-114 for 2 h by repeated disper-
sion through a bent constricted pipette tip, followed by centrifugation
at 100,000 
 
g
 
 to remove debris. Amphiphilic proteins in both the cytosol
fraction and the membrane extract were purified by temperature-
induced Triton X-114 phase separation
 
 
 
(5). The detergent phase of ei-
ther membrane or cytosol fractions was precleared with a normal hu-
man serum before immunoprecipitation with the indicated sera (21).
Extracts of 250–500 rat islets were used per immunoprecipitate. Im-
munoprecipitates were analyzed by SDS-PAGE using 15% gels and
processed for fluorography (21). A quantitative estimate of the
GAD
 
65
 
 and 38-kD protein immunoreactivity of sera (antibody index)
was obtained by densitometric scanning of bands corresponding to
the proteins on autoradiograms using a video densitometer (model
620) with 1D Analyst II and version 3.10 software (BioRad Laborato-
ries, Richmond, CA). Serum I
 
15
 
 was used as an internal 38-kD anti-
body positive control in all analyses and its value arbitrarily set at 10.
38-kD antibody indexes in other sera were calculated from integrated
peak areas by the formula: index 
 
5
 
 10 
 
3
 
 (value for unknown serum
 
2
 
 value for negative control serum)/(value for serum I
 
15
 
 
 
2
 
 value for
negative control serum). Similarly GAD
 
65
 
 antibody indexes were ex-
pressed in relation to a standard positive control serum which is a Ju-
venile Diabetes Foundation (JDF) world standard for ICA analyses
and is also used as a standard for quantitative analyses of GAD
 
65
 
 au-
toantibodies (22, 23). This serum was also used as a standard positive
control serum for analysis of IA2 antibodies (see below). The values
of GAD
 
65
 
 antibodies and IA2 antibodies, respectively, in this serum
were each arbitrarily set at 10. GAD
 
65
 
 antibodies in sera were also an-
alyzed by immunoprecipitation of [
 
35
 
S]methionine-labeled recombi-
nant human GAD
 
65
 
 expressed in COS-7 cells (23), an assay which
had a 100% sensitivity and 100% specificity in the First International
GAD Antibody Workshop (24). There was a complete correlation
between sera scored positive and negative, respectively, in the two
assays.
 
Analysis of IA2 antibodies.
 
Analyses of IA2 antibodies using im-
munoprecipitation of rat islet cell extracts require trypsinization of
either islet cell lysates or immunoprecipitates, which was not compat-
ible with analyses of GAD
 
65
 
 and the 38-kD antigen in the immuno-
precipitates. Therefore, IA2 antibodies were assayed by immuno-
precipitation of [
 
35
 
S]methionine-labeled fragment of human IA2
generated by in vitro transcription and translation of a partial cDNA
clone IA2ic in a pGEM-4Z vector containing an SP6 promoter (8) (a
gift of Dr. M. Christie, King’s College, London, United Kingdom).
IA2ic encodes the COOH-terminal region of IA2, encompassing the
40-kD tryptic fragment recognized by diabetes-associated antibodies.
IA2ic was transcribed and translated in vitro in the presence of
[
 
35
 
S]methionine (Amersham International, Little Chalfont, United
Kingdom) using a kit from Promega Corp. (Madison, WI). 25–50 
 
3
 
10
 
3
 
 cpm of labeled protein in 20 
 
m
 
l IMP buffer (10 mM Hepes/NaOH,
pH 7.4, 150 mM NaCl, 0.5 mM methionine, 10 mM benzamidine/HCl,
0.1 mg/ml BSA, 5 mM EDTA, 0.5% Triton X-114) was incubated
with 5 
 
m
 
l of serum overnight at 4
 
8
 
C, followed by absorption to 5 
 
m
 
g of
preswelled protein A–Sepharose in the same buffer for 1 h. The PAS
was washed five times in IMP buffer and once in H
 
2
 
O. Immunocom-
plexes were eluted in 20 
 
m
 
l of SDS sample buffer, analyzed by SDS-
PAGE and autoradiography. Immunoprecipitated IA2c was quanti-
tated by phosphorimaging and by liquid scintillation counting of 10 
 
m
 
l
of the eluate. IA2 antibody indexes are expressed in relation to a
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standard positive control serum (see above). This assay had a sensi-
tivity of 69% in type 1 diabetic patients and a specificity of 97% in the
1995 Immunology of Diabetes Antibody Workshop.
 
Cell lines.
 
The 
 
b
 
TC3 cell line was derived from a transgenic in-
sulinoma (25). The 
 
b
 
HC16 cell line was derived from hyperplastic
mouse islets (26). 
 
a
 
TC1 and 
 
a
 
TC2 are two cell lines derived from two
independent transgenic mouse glucagonomas and show some expres-
sion of insulin in addition to glucagon (reference 27 and our unpub-
lished results). The 
 
a
 
TC1-6 cell line was derived from a single cell
clone of 
 
a
 
TC1, selected for its 
 
a
 
 cell phenotype (glucagon expres-
sion). Both 
 
a
 
TC1-6 and 
 
a
 
TC2 were a gift from Dr. D. Hanahan (Uni-
versity of California San Francisco). The GT1.1 and GT1.7 cell lines
were derived from two independent single cell clones of a gonadotro-
pin-releasing hormone secreting tumor cell line, GT1, procured from
a transgenic mouse (28). The GT 1.1 and GT 1.7 were selected based
on a strong neuronal phenotype in culture and were a gift from Dr. R.
Weiner (University of California San Francisco). The human neuro-
blastoma cell line SKNSH (29) was a gift from Dr. W. Sadee (Univer-
sity of California San Francisco). The rat hepatoma cell line HTC
(30) was a gift from Dr. A. Reuser (Erasmus University). The human
melanoma cell line OMM1 was a gift from T. Luider (Erasmus Uni-
versity). All other cell lines (Table I) were obtained from the Ameri-
can Tissue Culture Collection (Rockville, MD). The 
 
a
 
TC and 
 
b
 
TC
cell lines were cultured as described earlier (25, 26). The SKNSH,
Kelly, GT1.1, and GT1.7 cell lines were cultured in RPMI 1640, sup-
plemented with 10% FCS, 100 
 
m
 
g streptomycin/ml, and 100 IU peni-
cillin/ml. The SKNSH cells were grown with and without 10 
 
m
 
M retin-
oic acid (Sigma Immunochemicals, St. Louis, MO), which has been
shown to enhance the neuroblastoid phenotype in this cell line (29).
All other cell lines were cultured in DME, supplemented with 10%
FCS, 100 
 
m
 
g streptomycin/ml, and 100 IU penicillin/ml. The culture
medium for the C6 cell line was supplemented with 10 
 
m
 
M retinoic
acid. Cells were grown to 70–80% confluency and labeled with
[
 
35
 
S]methionine according to established methods (21). Membrane
extracts were prepared, extracted, and subjected to Triton X-114
phase separation. Detergent phase aliquots corresponding to 1 
 
3
 
 10
 
6
 
cpm of labeled protein were used for each immunoprecipitate. Indi-
vidual cell lines were immunoprecipitated as described for neonatal
rat islets using serum I
 
15
 
 and serum C
 
1
 
. The immunoprecipitates were
analyzed by SDS-PAGE and fluorography (21).
 
Two-dimensional gel electrophoresis and determination of isoelec-
tric points.
 
Two-dimensional gel electrophoresis using isoelectric fo-
cusing or nonequilibrium pH-gradient gel electrophoresis in the first
dimension and SDS-PAGE in the second dimension was carried out
as described (21, 31). Gels were exposed to phosphorimaging plates
for 3–21 d and read at high amplification using an AGFA clinical
phosphor storage plate reader. The resulting 16-bit images were con-
verted to 8-bit images with a final spatial resolution of 
 
z
 
 200 
 
m
 
M
(1,024 
 
3
 
 1,024 pixels). The radioactive spots were analyzed by image
scanning using the Bio-Image software version 4.6 (Millipore, Bed-
ford, MA). The isoelectric points were determined by coelectro-
phoresis with carbamylated creatin phosphokinase charge chain
markers (BDH, Poole, Dorset, United Kingdom) and with total
HeLa cellular proteins containing several hundred marker proteins of
known relative molecular mass, pI, and location in the two-dimen-
sional pattern.
 
Description of patient groups and sera.
 
Sera were collected after
informed consent from the following groups of individuals: (
 
a
 
) 86
newly diagnosed Dutch, Finnish, and Swedish type 1 diabetic patients
(I
 
1–86
 
), including 15 that developed diabetes at 
 
,
 
 2 yr of age, and 71
that developed diabetes at 
 
.
 
 2 yr of age; (
 
b
 
) 65 Dutch and Finnish
control individuals (C
 
1–65
 
) including 15 at 
 
,
 
 2 yr of age, 50 at 
 
.
 
 2 yr of
age; and (
 
c
 
) 44 North-American and Dutch prediabetic individuals
(age 2.6–49.9 yr) (P
 
1–44
 
). The first (and sometimes only) serum avail-
able from the individuals in this group was sampled 3–85 mo before
clinical onset of type 1 diabetes.
 
ICA and immunofluorescence analysis.
 
ICA were analyzed by in-
direct immunofluorescence of frozen sections of human pancreas
from cadaveric kidney donors of blood group 0 (32–34). Samples
were titrated and end point titers were defined as the highest titer of
detectable ICA staining. Positive samples were expressed in JDF
units by comparing their end point dilution to a standard calibration
curve using the international JDF reference serum provided by the
Immunology of Diabetes Workshops (35). The test laboratories are
participants of the ICA proficiency program conducted under the
auspices of the Workshops (36). A titer of 10 JDF units was consid-
ered positive.
For double immunofluorescence analysis of human pancreas, fro-
zen sections were air dried for 20 min and incubated with one of the
following sera:
 
 
 
I
 
14
 
, I
 
15
 
, or I
 
31
 
, at different dilutions overnight. After a
15-min wash in PBS, 3% BSA, the slides were incubated for 30 min in
a mixture of rabbit antiglucagon (Dako, Glostrup, Denmark) and
rabbit antisomatostatin (Dako) both diluted 1:20 in PBS. After sev-
eral wash steps of 15 min each in PBS, 3% BSA, the slides were incu-
bated with a mixture of FITC-labeled swine anti–human IgG (Dako)
and tetramethyl rhodamine isothiocyanate–labeled goat anti–rabbit
IgG (Dako) at dilution 1:60 and 1:15, respectively. After a final wash,
the slides were covered in Vectashield (Vector, Burlingame, CA) and
viewed on an Aristoplan immunofluorescence microscope (Leica In-
struments, Wetzlar, Germany).
 
Deglycosylation of the 38-kD antigen.
 
The 38-kD antigen was iso-
lated from Triton X-114 detergent phase fractions of rat islet mem-
branes by immunoprecipitation with I
 
15
 
. The protein was eluted from
the protein A–Sepharose pellet by boiling for 3 min in 0.4 M Na-
 
Table I. Analysis of Expression of the 38-kD Protein in 
Different Cell Lines
 
Cell line Origin Expression
 
b
 
TC3 (ref. 25) Mouse pancreatic insulinoma pos
 
b
 
HC16 (ref. 26) Mouse hyperplastic islets pos
 
a
 
TC-2 (ref. 27) Mouse pancreatic glucagonoma pos
 
a
 
TC1.6 (ref. 27) Mouse pancreatic glucagonoma neg
GT1.1 (ref. 28) GnRH neuronal tumor pos
GT1.7 (ref. 28) GnRH neuronal tumor pos
Neuro 2A* Mouse neuroblastoma pos
C6* Rat glial cells pos
SKNSH (ref. 29) Human neuroblastoma neg
Kelly* Human neuroblastoma (pos)
Bowes* Human melanoma neg
Omm1* Human melanoma neg
CHO* Chinese hamster ovary neg
HeLa* Human ovarian adenocarcinoma neg
T47D* Human ductal breast carcinoma neg
Sk-NEP-1* Human nephroblastoma neg
Cos-1* Monkey kidney tumor neg
CV-1* Precursor of Cos-1 neg
HepG2* Human hepatocellular carcinoma neg
BHK-21* Baby hamster kidney neg
HTC (ref. 30) Rat hepatoma neg
TERA-2* Human teratocarcinoma neg
CCD-118Sk* Human fibroblast neg
Aliquots of Triton X-114 detergent phase purified membrane protein
fraction of each cell line, corresponding to 1
 
 3
 
 10
 
6
 
 cpm per immunopre-
cipitate, were immunoprecipitated with serum I
 
15
 
 and C
 
1
 
, respectively.
Immunoprecipitates were analyzed by SDS-PAGE and fluorography. A
strong 38-kD band was detected in the positive cell lines after a 3-d ex-
posure. In contrast, the 38-kD protein was not detected in any of the
other cell lines after a 1-mo exposure. *American Type Culture Collec-
tion. 
 
GnRH
 
, gonatotropin-releasing hormone.
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phosphate, pH 7.9, 1% SDS, and 0.7% 
 
b
 
ME, diluted twofold, supple-
mented with Nonidet P-40 (Calbiochem-Novabiochem, San Diego,
CA) to a final concentration of 2.5%, and divided into three aliquots.
One aliquot was frozen immediately, two aliquots were incubated
with and without 
 
N
 
-glycanase (Genzyme, Cambridge, MA) at 378C
for 18 h. All three samples were boiled in SDS sample buffer and an-
alyzed by SDS-PAGE and fluorography using a Bio Max film (East-
man Kodak Co., Rochester, NY).
Results
Solubilization of the 38-kD protein. In the course of analyzing
sera from type 1 diabetic patients for GAD65 autoantibodies
using Triton X-114 detergent phase purified membrane pro-
tein fractions from islets of Langerhans, we discovered reactiv-
ity to a second membrane protein of 38 kD (see Fig. 1, lanes I4,
I9, I14–I16). We have used these sera to characterize this 38-kD
species and to establish reliable conditions for its extraction,
which has facilitated screens to establish the incidence of 38-
kD autoantibodies in prediabetic and recent onset diabetic pa-
tients.
Extraction of the GAD65 antigen from islets of Langerhans
is complete after 30 min in 1% nonionic detergents. In con-
trast, the 38-kD protein is only sporadically detected in such
extracts by immunoprecipitation with a serum from a newly di-
agnosed type 1 diabetic patient, I15. In preliminary experi-
ments, several detergents (CHAPS, b-octyl-glucoside, sodium
deoxycholate, Triton X-114) were tested for their ability to ex-
tract the 38-kD protein. A 2% concentration of each detergent
effectively solubilized the 38-kD protein during a vigorous 2-h
extraction of islet cell membranes. Triton X-114 was selected
for all further experiments to facilitate a partial purification of
the 38-kD protein by a temperature-induced phase transition
and separation of amphiphilic membrane proteins into the Tri-
ton X-114 detergent phase.
The 38-kD protein is an amphiphilic b cell membrane glyco-
protein of pI 5.6–6.1. The relative insolubility of the 38-kD
protein suggested that it was membrane bound. Cytosolic and
membrane proteins were subjected to a Triton X-114 phase
separation to assess the amphiphilicity of the 38-kD protein
(Fig. 1). In contrast to the GAD65 autoantigen which is found
as a soluble hydrophilic, a soluble amphiphilic, and a mem-
brane bound amphiphilic form (37, 38) (Fig. 1, compare lanes
16 and 18), the 38-kD protein was only detected in the particu-
late fraction, where it partitioned into the detergent phase
(Fig. 1, lanes 15 and 16). Thus, the 38-kD protein is an am-
phiphilic membrane protein. The relative insolubility of the
38-kD protein suggests that it is an integral membrane protein
in contrast to GAD65, which is anchored to membranes via
lipid residues (38).
The 38-kD protein was detected as a broad band on fluoro-
grams of SDS gels, suggesting heterogeneity in size and/or
charge (Fig. 1). Two-dimensional gel electrophoresis using iso-
electric focusing in the first dimension and SDS-PAGE in the
second dimension (21, 31) revealed seven spots of similar rela-
tive molecular weight and isoelectric points of 5.6–6.1 (results
not shown).
The 38-kD protein is expressed in cells of neuroendocrine
origin. Immunofluorescence analysis of frozen sections of hu-
man pancreas, using serum I15 which had the strongest immu-
noreactivity to the 38-kD protein of all sera analyzed in this
study, showed bright staining of pancreatic islet b cells in the
islet b cell core and weak staining of some glucagon- and/or so-
matostatin-positive cells in the periphery (Fig. 2). The staining
pattern of sera I14 and I31 both of which had a weaker immu-
noreactivity to the 38-kD protein in immunoprecipitation ex-
periments was similar. Exocrine cells were negative. Human
type 1 diabetic sera often contain antibodies to several antigen
specificities, thus sera I14 and I15 were positive for antibodies to
IA2 as well as the 38-kD protein. Although serum I31 was neg-
ative for IA2 and GAD65 antibodies, it may still contain anti-
bodies to other ICA antigens. Therefore, the immunofluores-
cence experiments only show that the antigens recognized by
these sera are islet cell specific in the pancreas, but do not di-
rectly address the distribution of the target antigen(s) within
the islet.
Because of the limitations of the immunofluorescence anal-
ysis for cellular localization studies, using polyspecific human
sera, we analyzed the expression of the 38-kD antigen in cell
lines derived from different tissues by immunoprecipitation.
Figure 1. Immunoprecipitation 
of the 38-kD protein from Triton 
X-114 detergent phase purified 
particulate and cytosol fractions 
of islet cells by diabetic sera. Flu-
orogram of an SDS-PAGE 
showing immunoprecipitation 
of membrane and cytosol frac-
tions of [35S]methionine-labeled 
islet cell proteins with sera from 
newly diagnosed diabetic pa-
tients I1–I16 (lanes 1–18), a stiff-
man syndrome serum (lane 19), 
and sera from healthy controls 
C1–C3 (lanes 20–22). GAD65 
which splits into two bands, a 
and b, can be seen in immuno-
precipitates from both mem-
brane and cytosol fractions with 
serum from patient I16 (lanes 16 and 18) whereas the 38-kD protein is only detected in immunoprecipitates from the membrane fraction with se-
rum from patient I15 and I16 (compare lanes 15 and 16 with lanes 17 and 18).
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI118732
2776 Aanstoot et al.
These analyses detected expression of the 38-kD antigen in the
majority of islet- and brain-derived cell lines, but not in a vari-
ety of cell lines from other tissues (Fig. 3 and Table I). The
positive cell lines included the bTC3 cell line derived from a
transgenic mouse b cell tumor (25), bHC16 cell line derived
from hyperplastic mouse islets (26), one of two aTC cell lines,
derived from mouse glucagonomas (27), two cell lines GT1.1
and GT1.7 derived by single cell cloning from a mouse gona-
dotropin-releasing hormone neuronal tumor (28), and having
the highest degree of neuronal phenotype of the cell lines ana-
lyzed, Neuro 2A, a mouse neuroblastoma cell line, and C6, a
rat glial cell line, which had a neuronal phenotype when cul-
tured in the presence of retinoic acid. The human neuroblas-
toma cell line, Kelly, was borderline positive (Fig. 3). All other
cell lines were negative (Fig. 3 and Table I). Thus, expression
of the 38-kD protein seems to be restricted to cells of pancre-
atic islet and neuronal/glial origin.
The electrophoretic mobility of the 38-kD antigen varied in
different cell lines. Although the 38-kD protein had a similar
mobility in islets and islet-derived cell lines, the mobility was
lower in some neuronal cell lines (Fig. 3, lanes 5 and 11), sug-
gesting a variability in posttranslational modification(s) be-
tween different cell lines.
The 38-kD protein is an N-asp–linked glycoprotein and the
nonglycosylated core has a molecular mass of 22 kD. The broad
mobility of the 38-kD antigen on SDS gels, and its heterogene-
ity on two-dimensional gels, suggested that the protein under-
goes posttranslational modification(s). To address whether the
38-kD antigen is N-asp glycosylated, the protein was purified
from rat islets by immunoprecipitation and incubated with the
enzyme N-glycanase, which cleaves mature N-aspartic acid–
linked carbohydrate moieties. Fig. 4 shows that treatment of
the 38-kD antigen with N-glycanase results in a protein with a
molecular mass of 22 kD, suggesting that the protein core of
the 38-kD protein is a molecule of 22 kD, which undergoes an
extensive N-asp glycosylation resulting in an increase in molec-
ular mass of z 11 kD for the protein expressed in islets. The
variation in mobility on SDS gels observed for the 38-kD pro-
tein in neuronal and islet cell lines (Fig. 3) is likely to reflect
differences in glycosylation.
Autoantibodies to the 38-kD antigen are present in a sub-
group of newly diagnosed diabetic individuals and complement
GAD65 and IA2 autoantibodies. Using the improved method
for solubilization of the 38-kD antigen, we analyzed 38-kD an-
tibodies in 86 newly diagnosed type 1 diabetic patients and 65
healthy individuals by immunoprecipitation (Figs. 1 and 5 and
Table II). 16 patients (19%) and none of the healthy individu-
als were positive for antibodies to the 38-kD protein. In com-
parison 65 (76%) patients and none of the controls were posi-
tive for GAD65 antibodies. Six patients (7%) were positive for
38-kD antibodies but negative for GAD65 antibodies (Table
III). Thus, the cumulative incidence of GAD65 and/or 38-kD
antibodies in newly diagnosed type 1 diabetic patients was
83%. The incidence of ICA was 81%.
The 21 sera from newly diagnosed type 1 diabetic patients
which were negative for both 38-kD and GAD65 antibodies
were analyzed for antibodies to IA2 (Fig. 6, lanes 1–14). Seven
of the double negative sera were positive for IA2 antibodies.
Figure 2. Immunofluorescence analysis of human pancreas using a 38-kD antibody positive serum. Double immunofluorescence analysis of a 
frozen section of human pancreas stained with human type 1 diabetes serum I15 (dilution 1:100) and a mixture of rabbit antiglucagon and rabbit 
antisomatostatin antibodies. FITC-labeled secondary antiserum was used to visualize human IgG (left) and tetramethyl rhodamine isothiocya-
nate–labeled secondary antiserum was used to visualize rabbit IgG (right).
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Thus 78/86 (91%) of patients were positive for antibodies to ei-
ther one or more of the three autoantigens (Table II).
b cell destruction can progress for several years before the
first clinical symptoms of type 1 diabetes appear. It is conceiv-
able that the prolonged autoimmune destruction may result in
secondary autoimmune responses to molecules which are re-
leased from damaged b cells. Since the destruction of pancre-
atic b cells in children who develop type 1 diabetes at a very
young age must be rapid, we speculated that the antibody
specificities in such individuals may better reflect the primary
immune responses involved in b cell destruction than is the
case in individuals who have experienced many years of au-
toimmune response to b cells before the clinical onset. In addi-
tion to 38-kD and GAD65 antibodies, IA2 antibodies were an-
alyzed in all individuals, who developed diabetes , 2 yr of age.
Among the 15 patients in this age group, three children (20%),
who had a clinical onset of disease at 1.3, 1.6, and 1.8 yr of age,
respectively, were positive for 38-kD autoantibodies (Table
III). Of these three patients, two were positive for both IA2
and GAD65 antibodies, and one was positive for GAD65 au-
toantibodies but negative for IA2 autoantibodies (Table III).
14 patients (93%) were GAD65 antibody positive and 12 pa-
tients (80%) were positive for IA2 antibodies. The youngest
patient, who had a clinical onset of disease at 0.8 yr of age, was
positive for both GAD65 and IA2 antibodies. Only one patient
(1.7 yr) was negative for all three antibodies, and he was also
negative for ICA. Thus, all three antigens are targets of au-
toantibodies in these very young children.
The 38-kD antigen as well as GAD65 and IA2 are targets of
early B cell responses associated with b cell destruction. To fur-
ther assess whether the 38-kD antigen is a target of early
rather than late immune responses in type 1 diabetes we ana-
lyzed 38-kD antibodies in a group of 44 individuals (age 2.6–
49.9 yr at clinical onset) from whom sera were available 3–85
Figure 3. Expression of the 38-kD protein 
in islet and neuronal cell lines. Fluorogram 
of an SDS-PAGE analysis of immunopre-
cipitates of Triton X-114 detergent phase 
purified membrane protein fractions of the 
indicated cell lines using serum I15 (lanes with 
odd numbers) and serum C1 (lanes with 
even numbers). Equal numbers of cpm’s 
were used for each immunoprecipitate.
Figure 4. The 38-kD antigen is an N-asp–glycosylated protein. Fluo-
rogram of an SDS-PAGE analysis of immunoprecipitated 38-kD pro-
tein (lanes 4–6) incubated with (lane 6) and without (lane 5) N-glyca-
nase at 378C for 18 h. Lane 4 is an untreated sample stored at 2208C 
before SDS-PAGE analysis. Lanes 1–3 show a control immunopre-
cipitate treated identically.
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mo before clinical onset of type 1 diabetes (Figs. 7 and 8 and
Table II). The sera were also analyzed for GAD65 and IA2 au-
toantibodies (Table II). 6 of the 44 prediabetic individuals
(14%) were positive for 38-kD antibodies in the first serum
sample available, which was 3, 9, 25, 33, 53, and 74 mo, respec-
tively, before clinical onset of type 1 diabetes. Fig. 8 (lanes 3–
6) shows the analysis of 38-kD antibodies in an individual fol-
lowed from 53 to 20 mo before clinical onset.
Figure 5. Analyses of 38-kD and GAD65 autoantibodies in newly diagnosed type 1 diabetic sera. Immunoprecipitation of membrane fractions of 
[35S]methionine-labeled islet cell proteins with sera from newly diagnosed diabetic patients I15 and I62–I80 (lanes 3–21) and healthy controls C1 
and C31–C38. The diabetic sera recognize either the 38-kD protein alone, the GAD65 protein alone, both proteins, or no specific protein.
Table II. Incidence of Autoantibodies to a 38-kD b Cell Membrane Protein in Type 1 Diabetes and Comparison with GAD65 ab, 
IA2 ab, and ICA
Group n
Average age at
diagnosis or
sampling of
sera (controls) Range F/M ICA
Inc. of
38-kD
ab
Inc. of
GAD65
ab
Cumulative
inc. of 38-kD
and/or GAD65
ab
Cumulative
inc. of 38-kD
GAD65 and/or
IA2 ab
yr yr
Newly diagnosed
diabetic patients 86 8.868.7 0.8–57.0 35/51 70*/86 16‡/86 65/86 71/86 78/86
(0.7) (81%) (19%) (76%) (83%) (91%)
Healthy controls 63 9.868.2 0.9–54.2 28/35 0/63 0/63 0/63 0/63 N/A
(0.8) (0%) (0%) (0%) (0%)
Prediabetic individuals
3–85 mo before
clinical onset 44 19.2612.5 2.6–49.9 14/30 28§/44 6¶/44 33/44 35/44 37/44
(0.5) (64%) (14%) (75%) (80%) (84%)
*10 of whom were both GAD65 and 38-kD antibody negative, 3 of whom were GAD65, 38-kD, and IA2 ab negative. ‡14 of whom had GAD65 autoan-
tibodies, IA2 autoantibodies, or both. §One of whom was both GAD65 and 38-kD antibody negative, none of whom was GAD65, 38-kD, and IA2 ab
negative. ¶All of whom had GAD65 autoantibodies, IA2 autoantibodies, or both. Inc., Incidence; ab, antibodies.
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Among the 38-kD antibody positive prediabetic individu-
als, two were positive for both GAD65 and IA2 antibodies, two
were positive for GAD65 but not IA2 antibodies, and two were
positive for IA2 but not GAD65 antibodies (Table III). GAD65
antibodies were detected in a total of 33 (75%) of the predia-
betic patients in the first sample available 3–85 mo before clin-
ical onset of disease, a result consistent with earlier studies (39,
40). IA2 antibodies were detected in 20/44 (45%) of the predi-
abetic individuals. Thus the 38-kD as well as IA2 and GAD65
antibodies can be detected up to several years before clinical
onset. The cumulative incidence of 38-kD, GAD65, and IA2
autoantibodies was 84% in the prediabetic individuals. The in-
cidence of ICA in this group was 64% (Table II).
Follow-up samples were available for 34 of the prediabetic
individuals. None of the individuals changed from antibody
negative to antibody positive status in later samples. Thus, an-
tibody negative individuals remained negative and single anti-
body positive individuals did not become double or triple anti-
body positive in the observation period, suggesting that these
antibodies are not a consequence of prolonged b cell destruc-
Table III. Summary of Data on 38-kD Antibody Positive Individuals
No. Sex
Age at
onset
ICA
(JDF units)
GAD65 ab
index
38-kD ab
index
IA2 ab
index
Prediabetic samples
months before onset HLA-DR
I4 F 6.1 40 Neg 7.9 10.8
I9 M 5.7 Neg Neg 4.5 Neg
I14 F 4.8 40 Neg 1.3 5.8
I15 M 15.9 8 Neg 10.0 6.1 3, 4
I16 F 17.3 53 12.3 4.8 6.6 4, 4
I17 M 12.8 53 2.2 1.7 4.3 3, 4
I18 M 7.9 Neg 2.7 1.8 Neg 4, 4
I28 F 6.0 20 11.0 2.5 Neg
I29 M 12.1 . 1200 7.2 2.8 11.6
I30 M 33.6 400 Neg 1.8 4.5
I31 M 7.2 320 Neg 3.0 Neg
I44 F 10.9 40 14.0 1.7 Neg
I48 M 12.1 160 9.6 2.8 Neg
I66 F 1.6 610 6.5 8.8 1.0 4, 7
I67 F 1.3 275 4.6 1.6 Neg 1, 4
I80 M 1.8 285 8.7 1.7 5.1 7, 9
P5 F 5.5 160 Neg 4.1* 7.2 3 2, 3
P8 M 18.7 80 Neg 2.0* 8.7 33, 26 4, 4
P17 M 15.1 160 11.3 9.5* Neg 53, 41, 31, 20, 18, 3 4, 4
P18 M 14.1 160 7.0 5.8* 5.6 74, 18 3, 4
P33 M 5.1 80 4.3 3.9* Neg 9
P37 M 18.0 42 7.0 2.0* 8.6 25 1, 4
*38-kD ab index in first available sample.
Figure 6. IA2 antibody analysis in 38-kD/GAD65 antibody negative individuals and in 38-kD antibody positive individuals. Fluorogram of SDS-
PAGE analysis of immunoprecipitates of a COOH-terminal fragment of IA2, IA2ic, with 38-kD/GAD65 antibody negative sera (lanes 3–14) 
and 38-kD antibody positive sera (lanes 17–29). Lanes 1 and 15 show immunoprecipitates with a positive control serum. Lanes 2 and 16 show im-
munoprecipitates with a negative control serum. Several of the double antibody negative sera in lanes 3–14 are positive for IA2 antibodies, and 
several of the 38-kD antibody positive sera in lanes 17–29 are negative for IA2 antibodies.
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tion. Rather, they may be determined by genetic and/or envi-
ronmental factors which are either present or absent at the on-
set of the autoimmune process.
Four of the 38-kD antibody positive individuals were fol-
lowed regularly for a period of 30–48 mo after clinical onset.
Two of these (I17 and I18) were negative already 3 mo after clin-
ical onset (results not shown). I15 and I16 were still strongly an-
tibody positive at 3 mo after clinical onset, but became weakly
Figure 7. Analyses of 38-kD and GAD65 autoantibodies in prediabetic individuals. Immunoprecipitation of membrane fractions of [35S]methio-
nine-labeled islet cell proteins with sera from prediabetic individuals P1–P18 (lanes 3–21). The 38-kD protein is recognized by P5, P8, P17, and P18, 
3, 33, 53, and 74 mo, respectively, before clinical onset of type 1 diabetes.
Figure 8. 38-kD antibodies be-
fore and after clinical onset of 
type 1 diabetes. Fluorogram of 
SDS-PAGE analysis of immuno-
precipitates of membrane frac-
tions of [35S]methionine-labeled 
islet cell proteins with sera from 
different time points before 
(lanes 3–6) and after (lanes 8–12 
and 13–17) clinical onset of type 
1 diabetes.
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI118732
A 38-kD Glycosylated Islet Membrane Autoantigen in Human Type 1 Diabetes 2781
positive at 9 mo (Fig. 8). I15 was antibody negative at 18 mo
and onwards, whereas I16 remained weakly positive 18, 30, and
48 mo after clinical onset (Fig. 8). Thus, 38-kD antibodies in all
four individuals decreased significantly shortly after clinical
onset of diabetes.
Among all of the 22 38-kD antibody positive individuals in
the combined prediabetic and newly diagnosed groups of type
1 diabetic patients, 20 were positive for either GAD65 antibod-
ies (14/22), IA2 antibodies (13/22), or both (7/22). There was
no correlation between any two sets of antibodies in these indi-
viduals, suggesting that the antibodies to each of the three an-
tigens are separate entities which do not cross-react with the
other two antigens (Table III).
The 38-kD antibody positive sera did not recognize their
target antigen on Western blots, suggesting that 38-kD anti-
bodies, much as GAD65 and IA2 antibodies, are primarily di-
rected toward conformational epitopes (results not shown).
Regarding immune recognition, it is well established that
the MHC haplotype is influential. More than 90% of all indi-
viduals who develop type 1 diabetes are HLA-DR3 and/or
DR4 positive (41). HLA data could only be obtained for 12 of
the 22 38-kD antibody positive individuals (Table III). The
DR4 haplotype was particularly abundant in those individuals
(10/12 compared with 4/12 for DR3, and 2/12 for DR1 and
DR7, respectively). However the data set is too small to ana-
lyze for statistical significance.
Discussion
We have identified an islet cell N-asp–glycosylated membrane
protein, of 38,000 Mr, which is a target of immunoprecipitating
IgG autoantibodies in a subgroup of type 1 diabetic patients
and prediabetic individuals. The 38-kD protein is the third an-
tigen identified by immunoprecipitation in this disease, if the
tyrosine phosphatases that are precursors to the 37/40-kD
tryptic fragments are counted as one entity. The 38-kD antigen
shares the neuroendocrine expression pattern and conforma-
tional epitope characteristics of GAD65 and IA2.
Taken together among the 130 patients, who were analyzed
either in the prediabetic period or at the clinical onset of dis-
ease, 22 (17%) were 38-kD antibody positive (Table III) com-
pared with 98 (75%), who were GAD65 antibody positive. Two
patients were positive for 38-kD antibodies only, whereas 20
had GAD65 and/or IA2 antibodies in addition to the 38-kD an-
tibodies. Thus 106 (82%) were positive for antibodies to either
38-kD, GAD65, or both antigens. Among the 24 double anti-
body negative patients, 9 were IA2 antibody positive. Thus,
the cumulative incidence of all three antibodies was 91%. Both
GAD65 and IA2 antibodies were detected at clinical onset in a
child, who developed type 1 diabetes as early as 0.8 yr of age,
and 38-kD antibodies were detected in a child who developed
diabetes at 1.3 yr of age. Since the duration of b cell autoim-
munity in those very young children must have been signifi-
cantly shorter than is often the case in older individuals (39,
40), this result suggest that all three proteins may be targets of
primary rather than secondary autoimmune processes directed
to the b cell in the human disease. This notion is supported by
the appearance of antibodies to all three antigens several years
before the clinical onset of type 1 diabetes. Thus, antibodies to
all three antigens, GAD65, IA2, and the 38-kD protein mark
periods of early b cell destruction.
In the prediabetic group, the GAD65 antibody assay alone
detected 33/44 (75%) of the patients. A combination of GAD65
and 38-kD antibody assays detected 35/44 (80%), and a combi-
nation of IA2 and 38-kD antibody assays detected 22/44 (50%)
of the individuals. A combination of GAD65 and IA2 antibody
assays detected 37/44 (84%), which was the same as the cumu-
lative sensitivity for all three antibody assays.
The incidence of ICA detected by immunofluorescence of
frozen sections of human pancreas was 75% (98/130). In the
prediabetic and newly diagnosed groups, the 38-kD, and/or
GAD65, and/or IA2 immunoprecipitation assays detected a to-
tal of 19 individuals negative for ICA by the immunofluores-
cence assay, indicative of a lower sensitivity of the ICA
method to detect antibodies to these antigens. In the predia-
betic group all ICA-positive individuals (n 5 28) were positive
for either GAD65 antibodies, IA2 antibodies, or both. A com-
bination of GAD65 antibodies and 38-kD antibodies detected
all these individuals except one, whereas a combination of 38-
kD antibodies and IA2 only detected 15 of the ICA-positive
individuals. Among the 70 ICA-positive patients in the newly
diagnosed group, the cumulative antibody assays to all three
antigens detected all but three individuals. In these three indi-
viduals the humoral immune response may have evolved to fo-
cus on other target molecules by the time of clinical onset. Im-
munoprecipitation analyses did not reveal islet cell protein(s)
specifically recognized by those sera (results not shown). It is
conceivable that ICA reactivity in those 38-kD and GAD65 an-
tibody negative sera may be directed to nonprotein molecules
like gangliosides (42). Finally, seven individuals in the predia-
betic group and five individuals in the newly diagnosed group
were negative for antibodies by both immunofluorescence and
immunoprecipitation assays.
The 38-kD antigen is distinct from two diabetes-associated
antigens of similar apparent molecular mass previously de-
scribed, jun B and imogen 38. Its cellular expression pattern
differs from that of imogen 38, which was identified as a target
of a CD41 T cell clone derived from a type 1 diabetic patient
and has a wide tissue distribution (19). Furthermore, imogen
38 is not N-asp glycosylated (19) and does not seem to be a tar-
get of humoral autoantibodies in type 1 diabetes.
Honeyman et al. (20) reported the isolation of a cDNA
clone encoding jun-B by antibody screening of an expression
library from islets and placenta using a human serum from a
type 1 diabetic patient. They subsequently detected peripheral
T cell responses to jun-B in some type 1 diabetic patients and
their relatives and concluded that jun-B is a target autoantigen
in type 1 diabetes. jun-B has a molecular mass of 38 kD.
jun-B is a nonglycosylated, soluble nuclear protein and
therefore differs from the 38-kD protein described here. Fur-
thermore, rat jun-B has a pI $ 9 on two-dimensional gels and
the calculated pI for human jun-B based on the amino acid se-
quence (43) is 9.58. Finally, antibodies to jun-B do not immu-
noprecipitate the 38-kD antigen (our unpublished results). To
distinguish the novel 38-kD autoantigen described here from
jun B and imogen 38, we name it glima 38 (glycosylated islet
membrane antigen of 38 kD).
The relation between glima 38 and a diabetes-associated
(but as yet uncharacterized) antigen in the diabetes-prone BB
rat (18) is unclear. The BB rat protein migrates as a sharp band
on SDS gels, a characteristic inconsistent with the highly glyco-
sylated nature of glima 38, and thus appears to be different.
Glima 38 is not related to a 38-kD protein only detected in im-
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munoprecipitates from one preparation of DR3 positive hu-
man islets, using GAD65 antibody positive sera, and described
earlier (6), because none of these sera recognize glima 38. This
human islet 38-kD protein migrated as a sharp nonglycosy-
lated band and may have been a degradation product of
GAD65 in this particular preparation of human islets.
We have extensively analyzed immunoprecipitates of de-
tergent lysates of [35S]methionine-labeled islets with diabetic
and control sera by one- and two-dimensional gel electro-
phoresis in attempts to detect additional islet cell proteins that
are specifically and consistently recognized by autoantibodies
in type 1 diabetes under native conditions. The stringent con-
ditions of immunoprecipitation require that antibodies must
be of the IgG isotope (for binding to protein A–Sepharose)
and must be of sufficient affinity and specificity to recognize
their target protein in the midst of an abundance of other islet
cell proteins. Whereas this assay clearly detects the GAD65a/b
doublet as well as the 38-kD protein, in nonprotease condi-
tions, and the 40-kD IA2 and 37-kD tyrosine phosphatase
fragments in protease conditions, it does not detect carboxy-
peptidase H, a 69-kD protein with homology to BSA, or insu-
lin (reference 21 and our unpublished results) although reac-
tivity of those proteins with antibodies in diabetic sera has
been detected in other assays (11–13, 44). Thus, strong immu-
noprecipitating IgG responses to conformational protein
epitopes may be limited to the GAD65, 38-kD, and the tyrosine
phosphatase antigens in the human disease. An outstanding
question is whether GAD65, IA2, and the 38-kD antigens are
targets of pathogenic human T cells which are believed to me-
diate b cell destruction in type 1 diabetes (4), a result which
would suggest that these proteins have a potential for antigen-
specific immunotherapy aimed to eliminate or inhibit autoim-
mune T cells and prevent the disease in humans.
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